Web of Science: 8 cites, Scopus: 7 cites, Google Scholar: cites,
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Rottenkolber, Marietta (Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet)
Fischer, Rainald (Pneumologische Praxis Muenchen - Pasing, Munich, Germany)
Ibáñez, Luisa (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Fortuny, Joan (Novartis Farmaceutica SA)
Reynolds, Robert (Pfizer Research & Development, New York, USA)
Amelio, Justyna (Amgen Ltd, Uxbridge, UK)
Gerlach, Roman (National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany)
Tauscher, Martin (National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany)
Thürmann, Petra (Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany)
Hasford, Joerg (Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet)
Schmiedl, Sven (Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany)

Data: 2015
Resum: After the SMART trial evaluating the safety of salmeterol (long-acting beta-2-agonist (LABA)) in asthma patients, regulatory actions were taken to promote a guideline-adherent prescribing of LABA only to patients receiving inhaled corticosteroids (ICS). We aim to analyse LABA- and ICS-related prescription patterns after the SMART trial in Germany. Patients documented in the Bavarian Association of Statutory Health Insurance Physicians database (approximately 10. 5 million people) were included if they had a diagnosis of asthma and at least one prescription of LABA and/or ICS between 2004 and 2008. Annual period prevalence rates (PPRs) were estimated and Cochrane Armitage tests were used for time trend analyses. Highest annual PPRs were found for budesonide and the fixed combination of salmeterol/fluticasone. The proportion of "concomitant LABA and ICS users" increased from 52. 0 to 57. 6% within the study period, whereas for "LABA users without ICS" a slight decrease from 6. 5 to 5. 4% was found. In 2008, the proportion of patients with at least one quarter with a LABA prescription without concomitant ICS was highest in elderly, male patients (≈20%). In the majority of these patients, a concomitant diagnosis of COPD (i. e. asthma-COPD overlap syndrome [ACOS]) was present. Between 2004 and 2008, we found a moderate increase in guideline-adherent LABA prescribing in a representative German population. Elderly men received a significant number of LABA prescriptions without concomitant ICS probably due to ACOS. The online version of this article (doi:10. 1186/s12890-015-0051-x) contains supplementary material, which is available to authorized users.
Ajuts: European Commission 115004
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan aquestes es distribueixin sota la mateixa llicència que regula l'obra original i es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Matèria: Long-acting adrenergic beta-2-receptor agonists ; Inhaled corticosteroids ; Asthma ; COPD ; ACOS ; Drug utilisation study ; SMART trial ; Drug regulatory actions
Publicat a: BMC Pulmonary Medicine, Vol. 15 (may 2015) , ISSN 1471-2466

DOI: 10.1186/s12890-015-0051-x
PMID: 25943421


10 p, 619.3 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-01-31, darrera modificació el 2021-09-29



   Favorit i Compartir